Genmab touts positive trial data

Genmab announced positive results in the HuMax-CD20 Phase I/II dose escalation study to treat patients with active rheumatoid arthritis. In patients who received two doses of HuMax-CD20, 77 percent (20/26) obtained ACR20. Even on an intent to treat basis, which included six patients who did not receive both doses of HuMax-CD20, 63 percent (20/32) obtained an ACR20. For comparison, among the 7 placebo patients none achieved ACR20.

- here's the release for more information